InvestInfoAI
a16z Capital Management, L.L.C.

Q2 2025 · 13F-HR

a16z Capital Management, L.L.C.holdings as filed

Filed 2025-08-14 · accession 0001415889-25-021833

$312.9M
Reported value
10
Positions
2025-06-30
Period end
View analyzed profile →PRO

The Brief · a16z Capital Management, L.L.C. · Q2 2025

AI · grounded in 13F

a16z Capital Management, L.L.C. established a new position in RVMD valued at $101.1M. The fund also initiated stakes in OMDA for $84.4M and XYZ for $69.1M. Other new additions include MAZE, BIOA, and NAUT.

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
76155X100RVMDREVOLUTION MEDICINES INC$101.1M32.3%2,748,523CommonSOLE
68170A108OMDAOMADA HEALTH INC$84.4M27.0%4,614,574CommonSOLE
852234103XYZBLOCK INC$69.1M22.1%1,016,697CommonSOLE
578784100MAZEMAZE THERAPEUTICS INC$20.9M6.67%1,702,225CommonSOLE
09077V100BIOABIOAGE LABS INC$13.4M4.27%3,233,170CommonSOLE
63909J108NAUTNAUTILUS BIOTECHNOLOGY INC$12.8M4.09%17,653,917CommonSOLE
29479A108ERASERASCA INC$3.6M1.16%2,862,500CommonSOLE
683712103OPENOPENDOOR TECHNOLOGIES INC$3.3M1.06%6,200,821CommonSOLE
13463J101CAMPCAMP4 THERAPEUTICS CORP$3.1M0.98%2,125,339CommonSOLE
37611X209DNAGINKGO BIOWORKS HOLDINGS INC$1.2M0.39%108,568CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.